Category: Partners

Fully funded to complete construction in Quebec and advance Colombia validation as production and exploration plans at Montauban accelerate

VANCOUVER, BC / ACCESS Newswire / September 25, 2025 / ESGold Corp. (“ESGold” or the “Company”) (CSE:ESAU)(OTCQB:ESAUF)(FSE:Z7D) is pleased to provide a construction update on its Montauban Gold-Silver Project in Quebec, where development is progressing. The Company reports that building construction remains on track, with completion anticipated by mid-Q4 2025. ESGold is fully funded to complete Montauban and is positioned to move forward aggressively, while continuing preparatory work on its prospective initiative in Colombia.

See construction progress photos here

Recent Highlights

• Construction Advancing: Development work at Montauban continues to progress on schedule with building completion anticipated in Q4-2025

• Fully Funded: Recent financing provides all necessary capital to complete Montauban and validate the Company’s Colombia joint venture.

• Upcoming Catalysts: Concentrate test results from both Montauban and Colombia expected in the near-term.

• Exploration Upside: Systematic exploration planning underway at Montauban, technical work has identified large, continuous geological structures extending to 1,200 meters, underscoring the district-scale potential of the property.

• Colombia Momentum: Ongoing review of the Bolívar area reinforces confidence in validating, closing, and executing the Company’s expansion strategy.

Gordon Robb, CEO of ESGold, commented:
“We are extremely pleased with the steady progress at Montauban, where building construction is advancing on schedule and moving toward completion, anticipated by mid-Q4 2025. Thanks to recent funding, we are now in the position of being fully financed to complete Montauban and to advance preparatory work on our prospective initiative in Colombia. With concentrate test results pending and exploration planning underway, the months ahead will be transformative as we build cash flow at Montauban while unlocking long-term discovery potential across our portfolio. ESGold is building the foundation for scalable growth, and we are very excited about what lies ahead.”

Building Momentum at Montauban
Construction at the fully permitted Montauban project continues on track, with infrastructure development and building completion anticipated mid-Q4 2025. The facility is advancing toward readiness for equipment delivery and commissioning, aligning with the Company’s strategy to begin production in 2026.

Thanks to recent funding, ESGold is in a strong financial position to complete Montauban and advance its Colombia joint venture without the necessity of returning to the market for capital. Once the team arrives in Colombia for on-the-ground validation, ESGold will be fully equipped to close and execute.

In parallel with construction, ESGold is advancing exploration at Montauban. Despite over a century of historic mining, the deposit has never been systematically explored. Recent technical work has identified large, continuous geological structures extending to 1,200 meters, underscoring the district-scale potential of the property.

Why This Matters to Investors
This update reinforces ESGold’s unique position as a fully funded, fully permitted, near-term producer with significant exploration upside. Unlike most juniors that rely on continuous dilution, ESGold is advancing toward cash flow in 2026 while systematically unlocking discovery potential. The dual track model of cash flow today and discovery tomorrow positions the Company to deliver sustainable shareholder value through both near term production and long-term growth.

What’s Next

• Concentrate test results for both Montauban and Colombia.

• Colombia validation by ESGold’s technical team, followed by deal closure and execution.

• Comprehensive 3D geological model of Montauban currently in progress, designed to integrate ANT survey results and guide systematic exploration.

• Exploration at Montauban will progress to include systematic drilling to highlight the district-scale significance of the deposit.

ESGold is now fully funded and remains focused on advancing Montauban into production, with cash flow targeted for 2026. The Company’s strategy centers on completing construction at its fully permitted Quebec project, generating high-margin revenue from tailings reprocessing, and using that cash flow to fund systematic exploration across the land package. This disciplined approach minimizes dilution and compounds shareholder value over time. With Montauban as the blueprint, ESGold is building a scalable platform designed to deliver sustainable, long-term value for its shareholders.

Qualified Person Statement
The technical content of this news release has been reviewed and approved by André Gauthier, P.Geo., a Director of ESGold and a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Sampling described herein was conducted for due-diligence screening; independent verification, QA/QC, and systematic work remain outstanding. No mineral resources or reserves are declared.

About ESGold Corp.
ESGold Corp. (CSE: ESAU | OTCQB: ESAUF | FSE: Z7D) is a fully permitted, pre-production gold and silver mining company at the forefront of scalable clean mining and exploration innovation. With proven expertise in Quebec, the Company is advancing its Montauban Gold-Silver Project toward near-term production while unlocking long-term value through strategic redevelopment, modern discovery tools, and sustainable resource recovery. Montauban, located 80 km west of Quebec City, represents a blueprint for cash-flow-generating legacy site redevelopment across North America.

For more information, please contact ESGold Corp. at +1-888-370-1059 or visit esgold.com for additional resources, including a French version of this press release, past news releases, a 3D model of the Montauban processing plant, media interviews, and opinion-editorial pieces.

Stay connected by following us on X (formerly Twitter), LinkedIn, and joining our Telegram channel.

For further information or to connect directly, please reach out to Gordon Robb, CEO of ESGold Corp. at gordon@esgold.com or call 250-217-2321.

On behalf of the Board of Directors
ESGold Corp.
Paul Mastantuono
Chairman & COO
info@esgold.com
+1-888-370-1059

Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements regarding future production, cash flow, exploration results, project economics, and permitting. Forward-looking information is based on reasonable assumptions that management believes are current but involve known and unknown risks and uncertainties that may cause actual results to differ materially. These risks are detailed in the Company’s public filings on SEDAR+. Readers are cautioned not to place undue reliance on such statements. ESGold disclaims any obligation to update or revise any forward-looking information, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release

SOURCE: ESGold Corp

View the original press release on ACCESS Newswire

BOCA RATON, FL / ACCESS Newswire / September 25, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today proudly announced that the Company’s live coverage of the Charlie Kirk Remembrance Service from Phoenix delivered record-setting ratings, with over eight million Americans tuning in across its television platforms.

The service, which honored the life and legacy of one of the most influential conservative voices of his generation, resonated deeply with viewers nationwide.

Newsmax’s commitment to delivering meaningful, live coverage of moments that matter was met with an overwhelming response and unprecedented ratings success.

According to Nielsen data and internal streaming metrics:

• 8+ million total viewers watched Newsmax and Newsmax2 combined.

• 6+ million tuned into Newsmax’s cable channel, marking one of the network’s strongest live event performances to date.

• 2+ million streamed on Newsmax2, the network’s fast-growing streaming platform, showcasing Newsmax’s reach beyond traditional television.

• 2.5 million cable viewers were in the key demo A35-64.

• #2 in cable overall; Newsmax ranked just behind Fox News in total audience during coverage.

These results underscore Newsmax’s extraordinary growth and relevance, as Americans increasingly turn away from legacy media outlets in search of unfiltered, balanced coverage.

A National Moment of Remembrance

Charlie Kirk, founder of Turning Point USA, has been a prominent advocate for conservative principles, youth empowerment, and faith-based activism. He was a frequent guest on Newsmax, including during long periods he was banned from appearing on Fox News.

His remembrance service in Phoenix was a solemn yet inspirational gathering, drawing President Trump and the Kirk family, friends, political leaders and supporters from across the country.

Newsmax delivered live, uninterrupted coverage for eight hours, ensuring millions of Americans could take part in honoring Kirk’s contributions. The broadcast highlighted heartfelt tributes, stirring personal stories, and reflections on his enduring impact on conservative thought and grassroots movements.

“Americans are making the switch to Newsmax in historic numbers,” said Christopher Ruddy, CEO of Newsmax. “The overwhelming response to our coverage of the Charlie Kirk Remembrance shows that when a moment matters, people turn to Newsmax. We are proud to provide a platform that honors America’s values, traditions, and leaders like Charlie Kirk. We thank our viewers for placing their trust in us.”

About Newsmax
Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Investor Contacts
Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

Company continues to build momentum and continued positive client growth relative to prior years

VIRGINIA BEACH, VA / ACCESS Newswire / September 25, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., provides a shareholder update highlighting key achievements that represent progress and momentum year to date.

Inspire Veterinary Partners Chairman, CEO, and President Kimball Carr commented, “Inspire is back to growth and we are better positioned for success than ever before. Following our letter to shareholders earlier in 2025, we are very excited to continue to share the progress Inspire is making and how we’re seeing the benefits of our collective work reflected in our business. The company is consistently delivering positive results, new growth across a wide array of measures and KPIs ,and there is maturity in our systems and leadership team, which are delivering results on a daily basis. We’re looking forward to finishing strong in 2025 and springing forward toward increased growth in 2026.”

Accomplishments to date include:

• The highest new client growth in more than a year, with clinics across the portfolio achieving positive new client growth compared to 2024 and prior

• Completion of an enterprise-wide rollout of cloud-based Electric Medical Record (EMR) and Practice Management Software (PMS) across all clinics

• Deployment of Artificial Intelligence (AI)-based transcription for medical notes, enabling enhanced productivity and efficiency across the company’s business units

• Record breaking veterinarian hiring with nine new doctor starts since the beginning of 2025

• Completion of the company’s fifth acquisition in the state of Florida

• Signing of a Letter of Intent for a planned acquisition of the company’s first location in New Jersey, which will be the Company’s 15^th location nationwide

• A return to positive revenue comps as reported in Q2 2025

• Deployment of infrastructure investments including a new talent management system; new engagement, recognition and incentive-based pay structures; new finance professionals and enhancements to the company’s purchase and inventory management systems; new investor relations and investment banking partnerships

Mr. Carr continued, “Having solidified this progress, we now anticipate a strong end to the year, including the closing of our New Jersey acquisition, with several additional acquisition agreements anticipated for year-end and early 2026. We also are developing and preparing to launch new business verticals that will expand our offerings to clients, while simultaneously expanding key facilities across our network to provide broader service offerings and growth in existing clinics. Finally, we are working diligently to enhance our already world-class compensation and benefits plan to add equity offerings for all employees, which we believe will encourage future acquisition and expansion into new geographies. We remain enthusiastic and look forward to working closely with our partners to ensure a bright future for Inspire and look forward to providing updates as our progress continues.”

About Inspire Veterinary Partners, Inc.

Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: www.inspirevet.com.

Facebook | LinkedIn | X

Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding management’s expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption “Risk Factors” in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Investor Contact

CORE IR
516-386-0430
investors@inspirevet.com

Press Contact

CORE PR
Matthew Cossel
pr@coreir.com

General Inquires

Morgan Wood
Mwood@inspirevet.com

SOURCE: Inspire Veterinary Partners, Inc.

View the original press release on ACCESS Newswire

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally

SAN FRANCISCO, CA / ACCESS Newswire / September 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has received notice from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) of a $250,000 grant. Canalevia, under the name Canalevia-CA1, is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs. The grant would support a confirmatory study required for full FDA approval of Canalevia (crofelemer delayed-release tablets) for the treatment of CID in dogs. Acceptance of the award is dependent upon the company’s compliance with FDA terms and conditions. The company has not yet accepted the award.

“When an animal drug receives conditional approval, the CVM requires that a confirmatory trial take place within 5 years to provide the substantial evidence of effectiveness required for full approval of the drug for the indication,” said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar’s Vice President of Preclinical and Nonclinical Studies. “As announced, enrollment has begun in our ongoing full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs. Although we submitted the application for this grant in June 2024, notifications of successful grant awards were delayed due to the new federal administration and funding modifications by the National Institutes of Health. We are planning to request approval from the CVM to use the grant to support this ongoing, slightly modified, field study in dogs undergoing chemotherapy.”

“Looking forward, as announced, Jaguar is in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of Canalevia for the expanded indication of treatment of general diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “Our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs; obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; and maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs.”

Dogs undergoing chemotherapy are an important predictive model for crofelemer’s mechanism of action in humans experiencing diarrhea due to cancer treatment. Many cancer treatment agents provided to dogs are human drugs, or have the same mechanism of action as human cancer drugs, and these agents and mechanisms of action often have meaningful rates of diarrhea in humans as well. As announced yesterday, Jaguar family company Napo Pharmaceuticals has submitted an orphan drug designation application to the FDA for crofelemer for the treatment of diarrhea in adult patients receiving targeted therapy, with or without standard chemotherapy, for breast cancer that has metastasized to the brain.

A report by the American Veterinary Medical Foundation concluded that there were approximately 90 million dogs in the U.S. in 2024, of which Jaguar estimates more than 11 million suffer from general diarrhea each year. Data from the European Pet Food Industry Federation concluded that there were approximately 104 million dogs in Europe in 2022.

Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics. Canalevia-CA1, a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy.

Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.¹ According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.

Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will request approval from the CVM to use the grant to support the company’s ongoing, slightly modified, field study in dogs undergoing chemotherapy, and Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in dogs with general diarrhea. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

This launch represents a strategic expansion for tZERO, cultivating demand by equipping private companies with structured liquidity options, enhanced cap table control, and a natural pathway to tokenization.

NEW YORK CITY, NY / ACCESS Newswire / September 25, 2025 / tZERO, an institutional-grade platform and technology provider delivering compliant trading and tokenization solutions, has launched a Private Market Auction Facility service to help companies take control of their cap tables and provide investors and employee shareholders with a transparent way to buy and sell shares.

This initiative represents a new standard in how private companies can approach liquidity: structured, company-driven, and free from the inefficiencies of ad hoc transactions. Through tZERO’s innovative auction design and regulated infrastructure, issuers now have a tailored solution that keeps the focus where it belongs – on building their business.

To develop this solution, tZERO and its broker-dealer subsidiaries partnered with seasoned business development professionals, including John Murray, an exchange veteran with over 30 years of leadership across listed and unlisted markets, and Marc Philips, who brings more than 25 years of Silicon Valley founding and investing experience. Their expertise and deep connections across the innovation economy ensure the strategy is informed by real-world issuer and investor needs.

Private companies and their sponsors often face a choice between loss of control when employees and early investors look to sell their shares or limiting liquidity optionality for their long-standing supporters. tZERO’s new Private Market Auction Facility solves this challenge by giving issuers control over secondary activity – preserving cap table integrity while still enabling much-needed liquidity through an auction system.

tZERO’s auction facility begins with the issuer, unlike other liquidity platforms designed around buyers and sellers. The process is designed to give companies full control over participation, timing, frequency, and information sharing. Issuers can even bid to repurchase stock, ensuring fair treatment for employees and a level playing field for investors.

Key advantages include:

• Controlled ownership: Companies can determine who can bid at the auction – no surprises turning up on the cap table.

• Privacy and discretion: Due diligence access can be gated to protect against competitors accessing commercially sensitive company information.

• Fairness and efficiency: Auctions treat all sellers equally and ensure transactions occur at a market-determined price.

• Regulated broker-dealer led process that delivers a secure and compliant environment, with KYC, AML and other processes already taken care of by tZERO broker-dealers.

The tZERO auction model concentrates trading into defined moments, ensuring decisions are made at the auction rather than left to prolonged bilateral negotiations as on other platforms. This approach crystallizes the process, simplifies price discovery through a single “clearing price”, factors out the risk of enterprise values and NAVs being left at the mercy of unchecked continuous trading in niche environments and removes the burden of one-off negotiations – particularly valuable for employee shareholders less familiar with complex transactions.

tZERO provides a true white-glove service – handling everything from onboarding and escrow through the auction process, and coordinates directly with the transfer agent at settlement. The result is a secure, compliant, and issuer-friendly experience that lifts both the administrative and strategic burden from the C-suite.

“Private companies want liquidity solutions that reflect their unique needs,” said Alan Konevsky, CEO, tZERO. “With this auction facility, we’re not just solving for shareholder liquidity – we’re helping issuers activate their own networks, turning stakeholders into engaged participants in recurring marketplace events. Each auction strengthens ties with employees, early backers, and new participants, while laying the groundwork for tokenization and future capital formation. For tZERO, developments such as this provide another ramp for us to deploy tokenization and related services.”

“This product from tZERO is an outstanding innovation, providing bespoke trading facilities for companies wishing to remain private, I’m thrilled to be involved in the rollout,” added Murray.

By starting with structured auction events, issuers gain a foundation that can naturally extend into future digital strategies. The same infrastructure that supports fair and controlled secondary sales can also position companies to digitize ownership records, streamline shareholder management, and explore tokenized models for broader capital formation. This progression helps issuers meet current liquidity needs while keeping open the option to embrace more efficient, transparent structures as their business evolves.

For investors, the model provides the comfort of knowing there will be a regular liquidity event for mark-to-market, top-up purchases, or exits – helping them plan with greater confidence.

tZERO Group, Inc. is a pioneer in blockchain and tokenization innovation for financial markets, delivering institutional-grade technology and a regulated marketplace for tokenized securities and other assets. tZERO empowers issuers to digitize and manage their cap tables, while enabling investors, institutions, and broker-dealers to access liquidity in private assets. By combining compliance, security, and automation, tZERO is redefining how capital is raised, traded, and owned in the Web3 era.

–END–

Media Contact:

Julie Ros, Head of Marketing & Communications
jros@tzero.com

About tZERO

tZERO Group, Inc. (tZERO) and its broker-dealer subsidiaries provide an innovative liquidity platform for private companies and assets. We offer institutional-grade solutions for issuers looking to digitize their capital table through blockchain technology, and make such equity available for trading on an alternative trading system. tZERO, through its broker-dealer subsidiaries, democratizes access to private assets by providing a simple, automated, and efficient trading venue to broker-dealers, institutions, and investors. All technology services are offered through tZERO Technologies, LLC. For more information, please visit our website.

About tZERO Digital Asset Securities

tZERO Digital Asset Securities, LLC is a broker-dealer registered with the SEC and a member of FINRA and SIPC. It is the broker-dealer custodian of all digital asset securities offered on tZERO’s online brokerage platform. It operates in accordance with the SEC’s statement, dated December 23, 2020, regarding the Custody of Digital Asset Securities by Special Purpose Broker-Dealers. Digital asset securities may not be “securities” as defined under the Securities Investor Protection Act (SIPA)-and in particular, digital asset securities that are “investment contracts” under the Howey test but are not registered with the Securities and Exchange Commission are excluded from SIPA’s definition of “securities”-and thus the protections afforded to securities customers under SIPA may not apply. More information about tZERO Digital Asset Securities may be found on FINRA’s BrokerCheck.

About tZERO Securities

tZERO Securities, LLC is a broker-dealer registered with the SEC and a member of FINRA and SIPC. It is the operator of the tZERO Securities ATS. More information about tZERO Securities may be found on FINRA’s BrokerCheck.

Investor Notice

Digital asset securities, as well as any particular investment, may not be suitable or appropriate for everyone. Investors should note that investing or trading in securities could involve substantial risks, including no guarantee of returns, costs associated with selling and purchasing, and no assurance of liquidity which could impact their price and investor’s ability to sell, and possible loss of principal invested. There is always the potential of losing money when you invest in securities. There are also unique risks specific to digital asset securities, including, without limitation, fraud, manipulation, theft, and loss.

No Offer, Solicitation, Investment Advice or Recommendations

This release is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor does it constitute an offer to provide investment advisory or other services by tZERO or any of its affiliates, subsidiaries, officers, directors or employees. No reference to any specific security constitutes a recommendation to buy, sell, or hold that security or any other security. Nothing in this release shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction. Nothing contained in this release constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed in this release should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this release, we have not taken into account the investment needs, objectives, and financial circumstances of any particular investor. This information has no regard to the specific investment objectives, financial situation, and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors. Any views expressed in this release by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change. All information is subject to possible corrections. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.

Forward-Looking Statements

This release contains forward-looking statements. In addition, from time to time, tZERO, its subsidiaries, or its representatives may make forward-looking statements orally or in writing. These forward-looking statements are based on expectations and projections about future events, which is derived from currently available information. Such forward-looking statements relate to future events or future performance, including financial performance and projections; growth in revenue and earnings; and business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including, without limitation: the ability of tZERO and its subsidiaries to change the direction; tZERO’s ability to keep pace with new technology and changing market needs; performance of individual transactions; regulatory developments and matters; and competition. These and other factors may cause actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this release and other statements made from time to time by tZERO, its subsidiaries or their respective representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions. tZERO, its subsidiaries, and its representatives are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this release and other statements made from time to time by tZERO, its subsidiaries or its representatives might not occur.

SOURCE: tZERO Group, Inc

View the original press release on ACCESS Newswire

Company continues to innovate and invest in services, systems and processes to deliver a safe and seamless customer experience

MIAMI, FL / ACCESS Newswire / September 25, 2025 / Athena Bitcoin Global (OTC PINK:ABIT) (“Athena” or the “Company”), the number three international operator of Bitcoin kiosks and digital asset fintech solutions, is excited to announce a new credit and debit card capability that allows customers to securely and conveniently purchase Bitcoin online through the Athena website and the Athena App.

“Our mission has always been to make Bitcoin more accessible through new innovations that enhance the customer experience and enforce our commitment to comprehensive safety and security measures,” said Matias Goldenhorn, Chief Executive Officer of Athena. “By enabling credit and debit card payments online and through the app, we’re eliminating friction for customers who want a fast, secure way to buy Bitcoin and expanding our digital reach beyond physical kiosks.”

The new credit and debit card functionality is now live and supports Athena’s broader business strategy to increase customer convenience, strengthen retention, and drive growth across its digital and physical channels. The new functionality was developed in support of safe consumer transactions through continual investments in systems and processes as well as robust consumer education on the important role they have in protecting themselves from modern financial fraud.

To buy Bitcoin online with a debit card or credit card, Apple Pay, Google Pay, or Venmo visit athenabitcoin.com and click on Buy Bitcoin Online. Customers may also use the Athena Bitcoin App that must be downloaded to a smart phone from the Apple App Store or Google Play. To execute a digital exchange, follow the instructions to sign up, purchase, provide a wallet address, check out, and pay. Unlike banks, Athena does not take possession of customers’ bitcoin and does not hold customer balances. Customers retain full control of their assets in their own wallet apps.

About Athena Bitcoin Global

Athena Bitcoin Global operates an international network of Athena Bitcoin kiosks, which are freestanding kiosks that permit customers to buy or sell Bitcoin in exchange for fiat currencies. The Company places its machines in convenience stores, shopping centers, and other easily accessible locations in thirty-three U.S. states and territories, and in four countries in Central and South America. Athena Bitcoin Global’s comprehensive fintech platform enables POS merchant payments powered by Athena Pay, and the Company provides safe, reliable, and personalized trading services through its Athena Plus services. To learn more, visit www.athenabitcoin.com or follow Athena Bitcoin Global on Twitter and LinkedIn.

Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to anticipated user adoption, expansion opportunities, and technology integration timelines. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including market conditions, user demand, and regulatory considerations. Athena Bitcoin Global specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Rachele Andrejczak
Director of Marketing, Athena Bitcoin, Inc.
rachele@athenabitcoin.com
(786) 347-6242

SOURCE: Athena Bitcoin Global

View the original press release on ACCESS Newswire

Former KT Tape Senior Executive brings proven expertise in brand building, innovation, and consumer engagement

NORTH SALT LAKE, UTAH / ACCESS Newswire / September 25, 2025 / Handi Quilter, an international leader in long-arm and mid-arm quilting machines, systems, and accessories, today announced that its board of directors has appointed Zach Decker as Chief Executive Officer, following a national executive search. Decker succeeds Mark Hyland, who is retiring after 20 years as CEO.

“Zach is not only an accomplished brand builder but also a leader who truly understands passionate consumer communities,” said John S. Castle, President and CEO of Branford Castle Partners and Chairman of the Board of Handi Quilter. “As Chief Marketing Officer at KT Tape, he helped broaden the brand beyond elite and Olympic athletes to reach everyday people pursuing their physical goals. That ability to expand relevance and inspire confidence aligns perfectly with Handi Quilter’s mission to support quilters worldwide with innovation, education, and community.”

As a Senior Executive at KT Tape, Decker led brand strategy, product innovation, and omni-channel marketing, contributing to the company’s successful transaction in 2025 and helping KT Tape evolve from a brand primarily associated with serious athletes to one embraced by active people at every level. Earlier in his career, Decker held marketing roles with Kraft Foods, The Hershey Company, and Cricut, reinforcing his belief that creativity and making-whether crafting or quilting-should be accessible to everyone.

A graduate of the U.S. Naval Academy and a former Naval officer, Decker credits his service with shaping a disciplined, mission-driven leadership approach. He also holds an MBA from the University of Chicago Booth School of Business.

“Handi Quilter has a proud history of serving quilters around the globe with products designed by quilters, for quilters,” said Decker. “I’m excited to build on that legacy by championing meaningful innovation and sharpening how we communicate-so more people feel invited, confident, and inspired to quilt.”

Handi Quilter extends its deep appreciation to Mark Hyland for two decades of leadership that helped establish the brand’s global position in quilting.

About Handi Quilter
Founded in 1999 by Laurel Barrus, Handi Quilter is a globally recognized brand in quilting machinery and accessories, dedicated to innovation, quality, education, and community support. Headquartered in North Salt Lake, Utah, Handi Quilter serves quilters through a worldwide network of retailers, educators, and programs. Designed by quilters, for quilters®. Learn more at https://www.handiquilter.com.

About Branford Castle Partners
Branford Castle Partners is a leading private equity firm based in New York City, focused on investments in small- to mid-sized businesses. Learn more at https://www.branfordcastle.com.

SOURCE: Handi Quilter

View the original press release on ACCESS Newswire

SAN SALVADOR, SV / ACCESS Newswire / September 25, 2025 / Fundación Gloria Kriete (FGK), one of El Salvador’s most impactful philanthropic organizations since 2004, announced today a groundbreaking partnership with Big Interview, the leading global provider of job training and interview preparation tools. Beginning this September, the initiative will provide 25,000 Salvadoran job seekers with free access to Big Interview’s award-winning career readiness platform.

This collaboration represents a significant step in FGK’s mission to expand opportunity and economic mobility for underserved communities. By leveraging Big Interview’s powerful combination of expert-led video curriculum, interactive interview simulation, and AI-driven feedback tools, FGK aims to equip job seekers with the confidence and skills needed to thrive in today’s competitive labor market, both locally and abroad.

“This partnership is about more than just access, it’s about transformation,” said Roberto Kriete, Philanthropist, President of the Board of Fundación Gloria Kriete, and entrepreneur. “By connecting Salvadorans with cutting-edge job preparation tools, we’re opening doors to meaningful employment and long-term growth. We are proud to work with Big Interview to bring this vision to life.”

Big Interview, used by more than 2 million users worldwide, is trusted by workforce agencies, universities, and Fortune 500 companies alike. Its Spanish-language content and inclusive learning design make it an ideal fit for FGK’s broad national outreach, including youth, returning migrants, women, and individuals facing barriers to employment.

“We are honored to support Fundación Gloria Kriete’s incredible work,” said Steve Ruder, Vice President of Big Interview. “Together, we’re creating pathways to economic empowerment through practical, proven tools that help job seekers land the opportunities they deserve.”

The rollout is now underway, with a focus on ensuring access across FGK’s national network of education, entrepreneurship, and workforce development programs. Participating job seekers will receive tailored support, including curated job readiness tracks and real-time feedback on their interview skills.

About Fundación Gloria Kriete
Fundación Gloria Kriete is a non-profit organization dedicated to promoting development and social well-being in El Salvador through initiatives in education, health, entrepreneurship, and community empowerment. Learn more at https://fundaciongloriakriete.org

About Big Interview
Big Interview is an industry-leading online platform designed to help job seekers of all backgrounds build confidence and master their interview skills. Combining expert video lessons with AI-driven interview practice, Big Interview provides users with personalized feedback, real-time coaching, and tailored training for various industries and experience levels. Big Interview is used by 700+ non-profits, workforce agencies, Fortune 500 companies, universities, and government organizations to help job seekers secure employment 5X faster than the national average.

https://www.biginterview.com

Contact Information
Steve Ruder
Vice President, Big Interview
steve@biginterview.com

SOURCE: Big Interview

Related Images

View the original press release on ACCESS Newswire

Joins global brands Goldman Sachs, KITON, FLOKI, Ford Motors, and IMG Academy in going viral across NTTS’s YouTube and social media platforms

NEW YORK, NY / ACCESS Newswire / September 25, 2025 / New to The Street is proud to announce that its client Arrive AI (NASDAQ:ARAI) has surpassed 1 million views on its New to The Street TV commercials. The milestone reflects the growing impact of NTTS’s national broadcast and digital ecosystem, which has become a go-to media platform for innovative companies and world-class brands.

With commercials airing nationwide on Fox Business and Bloomberg, amplified by Times Square billboards and NTTS’s 3.5 million+ subscriber YouTube channel, Arrive AI has joined a roster of major brands – including Goldman Sachs, KITON, FLOKI, Ford Motors, and IMG Academy – that have achieved viral reach with NTTS’s signature “sponsored-to-earned” media model.

Vince Caruso, Co-Founder and CEO of New to The Street, stated:
“Arrive AI is breaking new ground in artificial intelligence, and their 1 million-plus commercial views demonstrate how fast the market is connecting with their story. At New to The Street, our mission is to give high-growth companies the same scale and visibility as global household names. We are thrilled to see Arrive AI join Goldman Sachs, KITON, FLOKI, Ford Motors, and IMG Academy as one of our most viral brands.”

The NTTS multi-platform model ensures commercial content not only reaches audiences during market-hour broadcasts, but continues to gain traction through YouTube, X, LinkedIn, Facebook, Instagram, and Reddit – driving measurable ROI for its clients.

About Arrive AI

Arrive AI (NASDAQ: ARAI) is a next-generation technology company leveraging artificial intelligence to transform how businesses and consumers interact with data, automation, and digital experiences. With innovative solutions across multiple industries, Arrive AI is building scalable tools to enhance efficiency and unlock new growth opportunities.

About New to The Street

Since 2009, New to The Street has been one of the longest-running U.S. and international sponsored and syndicated Nielsen-rated television brands, broadcasting weekly on Fox Business and Bloomberg as sponsored programming. With over 3.5 million YouTube subscribers, iconic Times Square billboards, and guaranteed earned media placements, New to The Street delivers its trademark “Opportunities To Consider™” segments, helping public and private companies tell their stories to investors, business leaders, and audiences worldwide.

Media Contact Monica@NewtoTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / September 25, 2025 / For nearly three decades, world leaders have gathered at United Nations Climate Change Conferences, flying in with the intention of collaborating and issuing declarations meant to inspire. Yet despite the sincerity of these efforts, the outcome at last year’s COP 29 felt all too familiar. Like the 28 before it, the summit ended with carefully crafted promises but little in the way of tangible results. The lesson is clear: debate does not recycle, and speeches cannot extinguish fires. The planet isn’t asking for more consensus – it’s asking for proof.

History shows that markets reward proof. Oil, steel, copper, and grain only became reliable global commodities once standards emerged to verify the quality of what was being traded. Without proof, there was no trust. Without trust, there was no value.

That is why companies like SMX (NASDAQ:SMX) are stepping in to close the gap. Instead of speeches, SMX offers technology embedded at the molecular level. Its markers make it possible to scan and confirm recycled content, validate flame-retardant safety, and even expose the so-called “ghost plastics” that conventional systems have never been able to track. Where conferences leave promises, SMX delivers proof woven directly into the materials themselves.

Ghost Plastics Made Visible, Verifiable, and Valuable

Ghost plastics have haunted the recycling industry for decades. Invisible to scanners, impossible to track, they slipped into landfills and incinerators by the billions of tons. These are high-value materials – carbon black from tires, flame-retardant plastics from electronics, construction compounds – yet they were written off as unrecyclable waste. A graveyard of performance materials hidden in plain sight.

SMX cracked the code. By embedding molecular markers, ghost plastics are no longer invisible. They can be identified, certified, and re-entered into the economy as tradable assets. A quick scan turns what used to be liability into inventory. For the first time, ghost plastics are not lost in the system; instead, they are priced into it.

That transformation doesn’t just restore efficiency; it creates a whole new supply stream. Verified ghost plastics command trust in the marketplace. Regulators can certify them, insurers can underwrite them, and manufacturers can use them without fear of claims collapsing under scrutiny. What was once buried is now a bankable resource.

Singapore, Europe, and NAFRA: Proof in Action

The difference between 29 well-intended conferences and SMX is traction. COP 29 produced another press release. SMX produced a plastics passport with Singapore’s A*STAR, where every piece of plastic carries a verifiable identity that regulators can enforce. This is not aspiration. It is enforcement backed by science.

In Europe, SMX’s planned partnership with REDWAVE is taking verification to the factory floor. Every plastic scrap on an industrial sorting line can now be scanned in real time. No waiting for audits, no reliance on self-reporting, no blind spots. It’s accountability embedded into the production process itself.

And in North America, SMX is proving to NAFRA it can make flame-retardant claims verifiable. For decades, the industry has fought to defend its reputation against skepticism. With molecular proof, NAFRA’s members don’t need defenses – they have evidence. Fire safety stops being a claim on a datasheet and becomes a fact embedded in every panel, appliance, and building material.

Proof Becomes the New Premium

Markets run on differentiation, and proof creates it. A verified recycled plastic with embedded proof is not the same as an unverified substitute. A verified fire-resistant panel is not the same as a datasheet promise. And a verified ghost plastic is no longer invisible waste but a certified commodity. Proof creates premiums, premiums create liquidity, and liquidity creates markets.

That is the inflection point SMX is driving. For manufacturers, proof means higher margins on verified goods. For insurers, proof means reduced risk and more accurate pricing. For governments, proof means policies that can be enforced by markets instead of endless penalties. For consumers, proof means labels they can actually trust. And for investors, proof means the birth of a new asset class – where recycling, safety, and ghost plastics are monetized together.

SMX has long said its mission is to turn sustainability from promise into proof. With even ghost plastics now visible, with A*STAR, REDWAVE, and NAFRA engaged, the company is proving something larger: proof is the new premium. The world doesn’t need more ballroom debates. It needs the molecule itself to testify. One SMX scan. Two proofs. That’s how real change begins.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters)

View the original press release on ACCESS Newswire